196 related articles for article (PubMed ID: 23674313)
21. Antiplatelet therapy in percutaneous coronary intervention: integration of prasugrel into clinical practice.
Thomas D; Giugliano RP
Crit Pathw Cardiol; 2009 Mar; 8(1):12-9. PubMed ID: 19258833
[TBL] [Abstract][Full Text] [Related]
22. Thienopyridine antiplatelet agents: focus on prasugrel.
Freeman MK
Consult Pharm; 2010 Apr; 25(4):241-57. PubMed ID: 20511177
[TBL] [Abstract][Full Text] [Related]
23. Prasugrel: new drug. After angioplasty and stenting: continue to use aspirin + clopidogrel.
Prescrire Int; 2009 Oct; 18(103):193-5. PubMed ID: 19877380
[TBL] [Abstract][Full Text] [Related]
24. Intensity of antiplatelet therapy in patients with acute coronary syndromes and percutaneous coronary intervention: the promise of prasugrel?
Wiviott SD
Cardiol Clin; 2008 Nov; 26(4):629-37. PubMed ID: 18929236
[TBL] [Abstract][Full Text] [Related]
25. Prasugrel: a guide to its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention in the US.
Lyseng-Williamson KA
Am J Cardiovasc Drugs; 2012 Jun; 12(3):207-16. PubMed ID: 22583148
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
27. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
Toth PP
Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of prasugrel compared with clopidogrel in patients with acute coronary syndromes: results of TRITON-TIMI 38 trials.
Mariani M; Mariani G; De Servi S
Expert Rev Cardiovasc Ther; 2009 Jan; 7(1):17-23. PubMed ID: 19105763
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Coleman CI; Limone BL
Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
[TBL] [Abstract][Full Text] [Related]
30. Prasugrel for acute coronary syndromes: faster, more potent, but higher bleeding risk.
Lazar LD; Lincoff AM
Cleve Clin J Med; 2009 Dec; 76(12):707-14. PubMed ID: 19952295
[TBL] [Abstract][Full Text] [Related]
31. A prospective observational study of treatment practice patterns in acute coronary syndrome patients undergoing percutaneous coronary intervention in Europe.
Ferrières J; Sartral M; Tcherny-Lessenot S; Belger M;
Arch Cardiovasc Dis; 2011 Feb; 104(2):104-14. PubMed ID: 21402345
[TBL] [Abstract][Full Text] [Related]
32. Study design and rationale of a comparison of prasugrel and clopidogrel in medically managed patients with unstable angina/non-ST-segment elevation myocardial infarction: the TaRgeted platelet Inhibition to cLarify the Optimal strateGy to medicallY manage Acute Coronary Syndromes (TRILOGY ACS) trial.
Chin CT; Roe MT; Fox KA; Prabhakaran D; Marshall DA; Petitjean H; Lokhnygina Y; Brown E; Armstrong PW; White HD; Ohman EM;
Am Heart J; 2010 Jul; 160(1):16-22.e1. PubMed ID: 20598967
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of intensive antiplatelet therapy with prasugrel from TRITON-TIMI 38 in a core clinical cohort defined by worldwide regulatory agencies.
Wiviott SD; Desai N; Murphy SA; Musumeci G; Ragosta M; Antman EM; Braunwald E
Am J Cardiol; 2011 Oct; 108(7):905-11. PubMed ID: 21816379
[TBL] [Abstract][Full Text] [Related]
34. Optimal medical therapy at discharge in patients with acute coronary syndromes: temporal changes, characteristics, and 1-year outcome.
Yan AT; Yan RT; Tan M; Huynh T; Soghrati K; Brunner LJ; DeYoung P; Fitchett DH; Langer A; Goodman SG;
Am Heart J; 2007 Dec; 154(6):1108-15. PubMed ID: 18035083
[TBL] [Abstract][Full Text] [Related]
35. Antiplatelet efficacy of prasugrel in patients with high on-clopidogrel treatment platelet reactivity and a history of coronary stenting.
Bernlochner I; Mayer K; Morath T; Orban M; Schulz S; Schömig A; Braun S; Kastrati A; Sibbing D
Thromb Haemost; 2013 Mar; 109(3):517-24. PubMed ID: 23328965
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of prasugrel in a US managed care population.
Mauskopf JA; Graham JB; Bae JP; Ramaswamy K; Zagar AJ; Magnuson EA; Cohen DJ; Meadows ES
J Med Econ; 2012; 15(1):166-74. PubMed ID: 22066985
[TBL] [Abstract][Full Text] [Related]
37. Oral antiplatelet therapy for the management of acute coronary syndromes: defining the role of prasugrel.
Devabhakthuni S; Seybert AL
Crit Care Nurse; 2011 Feb; 31(1):51-63. PubMed ID: 20592188
[TBL] [Abstract][Full Text] [Related]
38. Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event.
Thornley S; Marshall R; Chan WC; Kerr A; Harrison J; Jackson G; Crengle S; Wright C; Wells S; Jackson R
Eur J Prev Cardiol; 2012 Jun; 19(3):349-57. PubMed ID: 21450568
[TBL] [Abstract][Full Text] [Related]
39. Treatment pattern of contemporary dual antiplatelet therapies after acute coronary syndrome: a Swedish nationwide population-based cohort study.
Angerås O; Hasvold P; Thuresson M; Deleskog A; ÖBraun O
Scand Cardiovasc J; 2016; 50(2):99-107. PubMed ID: 26564402
[TBL] [Abstract][Full Text] [Related]
40. Prasugrel: Clinical development and therapeutic application.
Guerra DR; Tcheng JE
Adv Ther; 2009 Nov; 26(11):999-1011. PubMed ID: 20020231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
